MPR Weekly Dose 81 - A first therapy to target underlying process of Alzheimer disease; Moderna requests EUA; And a list of new approvals in a variety of therapeutic categories

<p><span style="font-weight: 400;">This week it's the big one: aducanumab - a treatment for alzheimer disease - got FDA approval. We’ll go into that, plus a semaglutide treatment for obesity, a first treatment for Plasminogen Deficiency Type 1, and Moderna have sent a request for an EUA to extend the use of their COVID-19 vaccine to those aged over 12.</span></p>